Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1537)	10/22/2004 10:16:16 AM
From: seminole	Respond to of 1826

Jason Zhang should add Aloxi (PONV) to his summary. IMO

To: Icebrg who wrote (1537)	11/6/2004 1:30:18 AM
From: Icebrg	Read Replies (1) \| Respond to of 1826

MGI Pharma initiated with "outperform" Friday, November 05, 2004 1:21:44 PM ET RBC Capital Markets NEW YORK, November 5 (newratings.com) - Analysts at RBC Capital Markets initiate coverage of MGI Pharma (XCYT.NAS) with an "outperform" rating. The target price is set to $35. In a research note published this morning, the analysts mention that the company’s growth is expected to be driven by the continued ramp-up of Aloxi’s sales and a robust product pipeline. MGI Pharma is expected to become profitable in 2005, the analysts add. Positive newsflow regarding the company’s various pivotal trials is likely in the near future, according to RBC Capital Markets.